LONDON, January 19, 2018 /PRNewswire/ --
Speciality European Pharma Limited ("SEP"), the parent of a European healthcaregroup, is pleased to announce the rebranding of itself and each of its subsidiaries as Contura ("the Group"). The rebrand will consolidate the Group under a single corporate identity and positions it for future growth.
(Logo: https://mma.prnewswire.com/media/630566/Speciality_European_Pharma_Logo.jpg )
Patrick Banks, Chief Executive Officer.
About SEP and Contura
The Group specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily in the fields of urology and urogynaecology. Its lead products are:
The Group was founded in 2000 and has built an experienced and accomplished management team. It came together as a result of SEP's acquisition of Contura A/S, a Danish company based in Copenhagen, in 2013. Contura A/S had two marketed products at the time of its acquisition, Bulkamid® and Aquamid®. It also had a number of development programmes focused on additional uses of its hydrogel technology.
In prospect, the opportunities for new products include:
The Group has an established sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. It has offices in the UK, Denmark, Germany, France and Italy and employs some 45 staff Europe wide.
Patrick Banks, CEO Phone number: +44 (0)20-7421-7400
Please visit our rebranded web page for further information: http://www.contura.com
SOURCE Speciality European Pharma Limited
Subscribe to our Free Newsletters!